Hypopituitarism Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Test Type (Hormone Deficiency Tests, Stimulation or Dynamic Tests, and Imaging Tests), By Sample Type (Blood, and Urine), By End-User (Clinical Laboratories, Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

Hypopituitarism refers to the condition in which the anterior and/or posterior pituitary gland is unable to secrete enough pituitary hormones in the body. Diagnosis of hypopituitarism can be done by measuring the basal pituitary hormone levels or by performing stimulation tests. Pituitary hormones such as GH, prolactin, LH, FSH, and others can be measured via sensitive and reliable immunoassay techniques. The increasing prevalence of hormonal problems, infections, or inflammatory diseases is leading to the increased patient population suffering from hypopituitarism.

• For instance, in February 2022, according to an article published in ELSEVIER the reported incidence of hypopituitarism is 42.1 cases per million, with a prevalence ranging from 290 to 455 cases per million.

Moreover, traumatic brain injuries can also cause hypopituitarism among patients due to several factors such as direct pituitary gland injury, infarction of the pituitary gland, and others. The increasing rate of these traumatic brain injuries often leads to higher rates of hypopituitarism in the patients. Also, other factors such as pituitary tumors, an increasing number of people suffering from genetic and autoimmune diseases, along with hectic life schedules leading to stress, sleeplessness, and others is further contributing to the increased prevalence of hypopituitarism among the patient population.

• In January 2023, according to a study published in mdpi, it is reported that traumatic brain injury affects almost 69 million people each year globally. Amongst these, 5% - 61% of patients have reported traumatic brain injury associated with hypopituitarism.

Thus, the increasing prevalence of hypopituitarism is shifting the key players’ focus on expanding the range of the products for immunoassay testing range products. Also, to cater to the rising demand for the advancement of these kits, key players are increasing their R&D investments with an aim to introduce advanced kits for the diagnosis of hypopituitarism in the market.  

• In November 2021, Bloom Diagnostics launched the smart thyroid hormone test to help detect the deficiency of thyroid stimulating hormone (TSH). Measurement of TSH can also enable physicians to diagnose the hypopituitarism condition among the patient population.   

Impact of COVID-19 on the Hypopituitarism Diagnostics Market 

The COVID-19 pandemic has positively impacted the hypopituitarism diagnostics market. The patients suffering from pituitary gland disease were at higher risk of COVID-19 due to existing comorbidities such as diabetes mellitus, obesity, and others. Also, the relationship between COVID-19 and hypopituitarism is bidirectional, as the COVID-19 virus can severely damage the pituitary gland and induce vascular events, subsequently leading to the loss of pituitary function among patients.

Increasing risk and severity of hypopituitarism has enabled doctors to prioritize suffering from hypopituitarism due to increased mortality rates in those patients. This has further led to increasing demand for these advanced diagnostic kits for the quick and efficient diagnosis of hypopituitarism among patients.  

Moreover, to cater to the rising demand the key players are focusing to launch advanced diagnostic kits. According to a 2021 article published by National Center for Biotechnology Information (NCBI), it was reported that patients suffering from hypopituitarism are at higher risk of COVID-19.

• Similarly, in November 2020, according to a research article published in NCBI, it was reported that patients with decreased or improper hormone secretion constitutes a higher risk of severity of COVID-19. This required the attention of specialists and doctors to these patients and thus, has increased the supply of these diagnostic kits worldwide.

Key Insights:

• Prevalence Of Hypopituitarism In Key Countries.
• New product launches, By Key Players.
• Key Industry developments- Partnerships, Mergers, and Acquisitions.
• Impact of COVID-19 on Hypopituitarism Diagnostics Market.

Analysis by Test Type:

Based on the test type, the market is bifurcated into hormone deficiency tests, stimulation or dynamic tests, and imaging tests. Among the test type, hormone deficiency tests hold the dominant position in the market owing to the increasing prevalence of various pituitary disorders among the patient population. The rising prevalence of these disorders is subsequently increasing the diagnosis rate of pituitary disorder, further leading to increased prescriptions of these hormone deficiency tests among physicians. Also, these hormone deficiency tests are generally performed to confirm the amount of the hormone released from the pituitary gland into the bloodstream. Thus, they are used as the first line of tests among patients. Therefore, the wide usage of these tests for the diagnosis of various pituitary disorders along with easy accessibility, and affordability contributes to the increasing demand for these hormonal deficiency tests in the market.

• For instance, in November 2022, according to an article published by NCBI, it is reported that 80% of patients are approximately affected with isolated ACTH deficiency. Thus, physicians generally prescribe these tests to confirm hormone deficiency among patients.

On the other hand, dynamic or stimulation tests are also anticipated to register considerable growth. This is attributed to increasing diagnosis for specific hormonal tests owing to the increasing prevalence of isolated or combined hypopituitarism. This increased patient rate is enabling the key players to invest in research and development activities for the launch of these tests in the market.                 

Regional Analysis: 

To gain extensive insights into the market, Download for Customization

North America market holds the largest share in the market due to the rising prevalence of hypopituitarism in this region. The increasing prevalence of this condition is enabling the government to focus on initiatives to spread awareness about the early diagnosis of this condition leading to growing demand for diagnosis among the patient population.

• For instance, in February 2021, according to an article published in Frontiers, it was reported that the incidence of hypopituitarism in neonates is 1 in every 4,000 to 1 in every 10,000 in the U.S.

On the other hand, Asia Pacific is anticipated to register comparatively higher growth during the forecast period. This is attributed to the rising awareness about the early diagnosis of hypopituitarism among patients. This is further leading to increased healthcare spending and thus enabling the key players to focus on research and development activities to introduce advanced diagnostics in the hypopituitarism diagnostics market.

Key Players:

The report will include the profiles of key players such as Abbott, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., bioMérieux SA, Danaher, QIAGEN, and others.

Segmentation:

Key Industry Developments:

• December 2022: bioMérieux SA announced the CE approval of VIDAS KUBE, the next generation automated immunoassay system with an aim to increase their diagnostic range. VIDAS KUBE is compatible with broad range of diseases and covers critical care, infectious diseases and others.
• June 2019: Abbott launched its new point-of-care A1c blood test with an aim to improve the diagnosis of diabetes. Pituitary hormones controls the glucose metabolism in the body and the deficiency of these hormones can cause hypoglycemia which can be diagnose with this A1C blood test.